Clinical Trial Update: Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating trametinib alone or with dabrafenib in cancers with V600 mutations or plexiform neurofibromas; completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Plexiform Neurofibromas

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-07-14